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Background. Many studies have demonstrated a causal link between Zika virus 
(ZIKV) infection, microcephaly (MCP), and other congenital abnormalities (CA). 
This study aimed to determine perinatal case fatality rate in cases of Congenital Zika 
Syndrome (CZS) in the Rio Grande do Norte State (RN), a Brazilian Northeast State 
highly impacted by the Zika virus outbreak.
Methods. A cross-sectional study was conducted using data obtained through 
the State Health Department (SHD) for cases of MCP and CA in Rio Grande do Norte 
from April 2015 to February 5, 2016. Definition of perinatal period: commences at 22 
completed weeks (154 days) of gestation and ends seven completed days after birth.
Results. During the study period, there were 486 cases of MCP and others CA 
notified in RN, of which 142 were confirmed and 108 remain under investigation. The 
remaining 236 cases have been ruled out by presenting normal examinations or due to 
presenting microcephaly by noninfectious causes. Of the total confirmed cases, 26.7% 
(38/142) died after birth or during pregnancy. 15.78% (06/38) of confirmed deaths had 
ZIKV infection during pregnancy and 2.63% (01/38) had a positive TORCH blood test. 
The six cases related to ZIKV were confirmed by RT–PCR and/or IgM/IgG antibodies 
against ZIKV. The remaining cases of deaths remain either under investigation or have 
been ruled out.
Conclusion. This study highlights a high rate of perinatal lethality (15.78%) in 
cases of CZS. Despite the growing number of CZS cases, the real incidence and prev-
alence might be higher due to the underreporting and lack of resources for confirma-
tory diagnostic tests (laboratory and imaging). Due to the high rate of lethality and 
the ongoing uncontrolled ZIKV outbreak, this study predicts an increase in the infant 
mortality rate in Brazil and highlights the need for developing public health programs 
to control the ZIKV outbreak.
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Background. Up to 15% of pregnancies complicated by maternal ZIKV infection 
result in Zika-virus associated brain abnormalities in the fetus/newborn. Fetal ultra-
sound (feUS) is the standard imaging modality for the evaluation of fetal anatomy 
and for brain changes from congenital infection. Fetal MRI (feMRI) may be a useful 
adjunct.
Methods. We performed a prospective longitudinal neuroimaging study of 
fetuses/newborns of pregnant women with clinical and/or lab confirmed (RT-PCR 
and/or IgM/PRNT) diagnosis of Zika infection in Barranquilla, Colombia (endemic) 
and in Washington, DC, USA (travel-related). Gestational age (GA) at exposure and 
timing between ZIKV exposure/symptoms and imaging was documented. Subjects had 
one to two feMRIs and feUS, depending upon GA at enrollment. The feMRI and feUS 
protocols were standardized between sites and studies were centrally interpreted at 
Children’s National. Postnatally, infants received an unsedated brain MRI and head US.
Results. Forty-eight, ZIKV exposed/infected in first or second trimester preg-
nant women were enrolled (46 Colombia, 2 USA). Subjects had symptoms of ZIKV 
infection at mean of 8.4 ± 5.7 week GA. The first feMRI and feUS were performed at 
25.1 ± 6.3 week GA. Thirty-six infants had a second feMRI and feUS at 31.1 ± 4.2 week 
GA. Three of 48 (6%) cases had an abnormal feMRI: (1) heterotopias and abnormal 
cortical indent; (2) parietal encephalocele and Chiari II; (3) thin corpus callosum, dys-
plastic brainstem, temporal cysts, subependymal heterotopias, and generalized cere-
bral/cerebellar atrophy. FeUS in these three cases found (1) normal study; (2) parietal 
encephalocele and Chiari II; (3) significant ventriculomegaly with decreasing percen-
tiles of head circumference from 32 to 36 week GA (38% to 3.6%). Postnatal head US 
revealed findings not seen on feUS: choroid plexus or germinal matrix cysts in nine 
infants and lenticulostriate vasculopathy in one infant.
Conclusion. FeMRI and feUS provide complimentary information in the assess-
ment of fetal brain changes in ZIKV. In cases of abnormal brain structure, feMRI 
reveals more extensive areas of brain damage than is seen by US. Further studies are 
needed to determine whether cystic changes on postnatal head US are related to ZIKV 
infection, or are incidental findings.
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Background. Perinatal HSV is associated with ~60% mortality if untreated and 
with substantial morbidity even with appropriate therapy. We recently engineered a 
single-cycle virus deleted in glycoprotein-D (ΔgD-2) that induces high-titer antibodies 
(Abs) that are non-neutralizing but activate the Fc receptor (FcR) to elicit antibody-de-
pendent cellular cytotoxicity (ADCC). Immunization with ΔgD-2 completely protects 
adult mice from HSV-1 and HSV-2 disease following vaginal, skin, intraocular, or 
intranasal challenge and prevents the establishment of latency (ELife, 2014, JCI Insight, 
2016). Thus we hypothesize that maternal immunization with ΔgD-2 and/or passive 
transfer of immune serum will protect neonates from HSV.
Methods. Four- to 6-week-old C57Bl/6 female mice were primed and boosted at 
3-week intervals with ΔgD-2 or an equal volume of uninfected cell lysates (VD60 cells). 
Two weeks post-boost, mice were mated and pups were challenged with a lethal dose 
of HSV-1 (Bx31.1) at day 7 of birth. To differentiate the contribution of transplacental 
vs. colostrum Abs, mothers were switched at birth. Alternatively, 7-day-old mice born 
to nonimmunized mothers received a single dose of immune serum (400 μg total Ab) 
intraperitoneally at time of intranasal challenge.
Results. Thirty-eight of 47 (81%) of the pups born to and nursed by ΔgD-2-
immunized mothers survived, exhibited little or no signs of disease and were protected 
from latency as measured by quantifying HSV DNA by PCR in neuronal tissue. In 
contrast, 12/14 (86%) of pups born to control vaccinated and nursed mice developed 
neurological signs of disease and died (P < 0.0001, Fisher’s exact test). Survival was 
associated with increased ADCC Abs in the serum of neonatal mice. In contrast, pas-
sive transfer of immune serum, which consistently protects adult mice from infection, 
did not protect neonates. If newborns born to immunized mice suckled with control 
mice, protection was partially abrogated (11/19, 58% survival), suggesting that both 
systemic and mucosal Abs are required for complete protection.
Conclusion. Maternal vaccination with ΔgD-2 provides significant protec-
tion against intranasal neonatal challenge but may require exposure to systemic and 
mucosal Abs.
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Background. Sensorineural hearing loss (SNHL) and neurodevelopmental (ND) 
outcomes are favorably impacted by antiviral therapy in infants with symptomatic 
cCMV disease. We correlated blood VL before and during therapy with clinical find-
ings at presentation and follow-up in this population.
Methods. Post-hoc analysis of two clinical trials conducted by the CASG from 
2002 to 2013 evaluating valganciclovir therapy. 120 subjects (73 treated × 6 weeks, 47 
